UNIGE document Scientific Article
previous document  unige:35201  next document
add to browser collection
Title

A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study

Authors
Published in American Journal of Gastroenterology. 2007, vol. 102, no. 7, p. 1397-405
Abstract In patients with cirrhosis, acute octreotide administration may transiently decrease the hepatic venous pressure gradient (HVPG). Information on long-term effects of octreotide is limited and controversial. We evaluated portal and systemic hemodynamics following a prolonged administration of long-acting octreotide in patients with cirrhosis.
Keywords AdultAgedBiological Markers/bloodBiopsyDelayed-Action PreparationsDouble-Blind MethodEndothelin-1/bloodFemaleFollow-Up StudiesGastrointestinal Agents/administration & dosage/pharmacokineticsHumansHypertension, Portal/drug therapy/etiology/physiopathologyImmunoenzyme TechniquesInjections, IntramuscularLiver Cirrhosis/blood/complications/pathologyMaleMiddle AgedOctreotide/administration & dosage/pharmacokineticsPortal Pressure/physiologyRadioimmunoassayRetrospective StudiesTime FactorsTreatment OutcomeUrotensins/bloodVascular Endothelial Growth Factor A/blood
Identifiers
PMID: 17488248
Full text
Article (Published version) (150 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research groups Hépatologie chirurgicale (327)
Physiopathologie de la pancréatite aiguë (601)
Citation
(ISO format)
SPAHR, Laurent François Joséph et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. In: American Journal of Gastroenterology, 2007, vol. 102, n° 7, p. 1397-405. doi: 10.1111/j.1572-0241.2007.01262.x https://archive-ouverte.unige.ch/unige:35201

387 hits

0 download

Update

Deposited on : 2014-04-01

Export document
Format :
Citation style :